1. A 72-year-old man with a history of myocardial infarction three years ago, heart failure with reduced ejection fraction (HFrEF, LVEF 32%), and now symptomatic persistent atrial fibrillation presents for antiarrhythmic selection. His creatinine clearance (CrCl) is 38 mL/min. Rate control alone has not adequately controlled his symptoms. His cardiologist is choosing between amiodarone and dofetilide. Which of the following best describes the correct selection and the reasoning that governs it?
A) Dofetilide is preferred because it has demonstrated survival benefit in HFrEF patients in the DIAMOND-CHF trial (Danish Investigations of Arrhythmia and Mortality on Dofetilide in Congestive Heart Failure), while amiodarone was associated with excess mortality in SCD-HeFT and should be avoided in this population
B) Amiodarone is preferred because dofetilide requires in-hospital initiation with QTc monitoring while amiodarone can be initiated safely as an outpatient, making it more practical for this patient with multiple comorbidities
C) Amiodarone is the appropriate choice; dofetilide is contraindicated in this patient because his CrCl of 38 mL/min falls below the 40 mL/min threshold for the AF indication, while amiodarone is hepatically cleared and safe in renal impairment; amiodarone did not increase mortality in HFrEF in SCD-HeFT, though it also did not improve survival
D) Dofetilide is preferred because its renal dose adjustment protocol allows safe use at CrCl as low as 20 mL/min with appropriate dose reduction, making it the better choice for a patient with CKD and HFrEF in whom amiodarone's pulmonary toxicity risk is elevated by reduced renal drug clearance
E) Neither agent is appropriate; this patient's combination of HFrEF, prior MI, and CKD makes all antiarrhythmic drugs contraindicated, and catheter ablation of the AF should be pursued as the only evidence-based intervention in this clinical profile
ANSWER: C
Rationale:
This question requires integrating three simultaneous clinical constraints: HFrEF, prior MI, and renal impairment. Working through each agent systematically is the correct approach. Dofetilide is contraindicated in this patient because his CrCl of 38 mL/min falls below 40 mL/min, the threshold specified in the FDA label for the AF indication below which dofetilide is not approved regardless of dose adjustment. This eliminates dofetilide as an option. Flecainide, propafenone, and dronedarone are all contraindicated by the structural heart disease (prior MI and HFrEF). Sotalol is contraindicated by both the renal impairment (CrCl below 40 mL/min) and the structural heart disease context. Amiodarone remains the only appropriate agent. Its pharmacokinetics are hepatically driven with negligible renal elimination, so the CKD does not affect its clearance or require dose adjustment. Amiodarone's safety in HFrEF is supported by the SCD-HeFT trial (Sudden Cardiac Death in Heart Failure Trial), which enrolled HFrEF patients and found that amiodarone did not increase mortality compared with placebo (unlike Class Ic agents in CAST (Cardiac Arrhythmia Suppression Trial)), though it also did not improve survival. Amiodarone remains guideline-supported for rhythm control in patients with structural heart disease when other agents are contraindicated. Its multi-organ toxicity profile requires systematic monitoring, but this does not constitute a contraindication.
Option A: Option A is incorrect in its characterization of the evidence: the DIAMOND-CHF trial enrolled patients with HFrEF and demonstrated that dofetilide was neutral on mortality and effective for AF rhythm control, which supports its use in HFrEF when renal function permits; however, this patient's CrCl of 38 mL/min precludes dofetilide use; additionally, SCD-HeFT showed amiodarone was neutral on mortality in HFrEF, not harmful.
Option B: Option B is incorrect: while amiodarone does not require in-hospital QTc monitoring in the same manner as dofetilide or sotalol, this is not the primary basis for the selection; the fundamental reason dofetilide is excluded is renal contraindication, not logistical inconvenience.
Option D: Option D is incorrect: the dofetilide label does not permit use below CrCl 40 mL/min for the AF indication, regardless of dose reduction; the tiered dose adjustment applies to patients with CrCl between 40 and 60 mL/min; below 40 mL/min the drug is contraindicated, not merely dose-reduced.
Option E: Option E is incorrect: while catheter ablation is an evidence-based option for AF and may ultimately be appropriate in this patient, stating that all antiarrhythmic drugs are contraindicated is incorrect; amiodarone is appropriate in this clinical profile.
2. A 67-year-old man has been on amiodarone 200 mg daily for four years for recurrent sustained ventricular tachycardia. He presents with a three-month history of progressive exertional dyspnea and a nonproductive cough. A chest CT scan shows bilateral ground-glass opacities and interstitial infiltrates without consolidation. His oxygen saturation on room air is 91%. Pulmonary function testing reveals a reduced diffusing capacity for carbon monoxide (DLCO). Amiodarone pulmonary toxicity (APT) is suspected. Which of the following best describes the correct management and the critical pharmacokinetic consideration that complicates recovery?
A) Amiodarone should be reduced to 100 mg daily rather than discontinued, as dose reduction below the toxicity threshold is sufficient to halt pulmonary inflammation while maintaining antiarrhythmic protection; full discontinuation risks recurrent ventricular tachycardia without a period of overlap antiarrhythmic therapy
B) Amiodarone should be discontinued immediately and high-dose corticosteroids initiated; because amiodarone is renally eliminated, age-related decline in creatinine clearance will extend its effective half-life, and the drug will remain pharmacologically active for several weeks before clearance is complete
C) Amiodarone should be immediately substituted with dronedarone, which lacks the iodine moiety responsible for pulmonary toxicity and provides equivalent antiarrhythmic protection for ventricular tachycardia in structural heart disease
D) Amiodarone pulmonary toxicity is fully reversible within two to three weeks of drug discontinuation because the pulmonary compartment clears amiodarone more rapidly than other tissues through alveolar macrophage-mediated elimination; corticosteroids are not indicated and may worsen the inflammatory response
E) Amiodarone should be discontinued and corticosteroids considered for moderate to severe cases; the critical pharmacokinetic complication is amiodarone's extremely long elimination half-life of weeks to months, arising from extensive accumulation in lipid-rich tissues including lung, adipose tissue, and liver; drug effect and potential for ongoing toxicity persist long after discontinuation, pulmonary improvement may take months, and the antiarrhythmic action also persists, providing a partial bridge during this period
ANSWER: E
Rationale:
Amiodarone pulmonary toxicity (APT) is the most life-threatening non-cardiac adverse effect of long-term amiodarone therapy and requires prompt drug discontinuation. The fundamental principle governing management is that amiodarone cannot simply be dose-reduced when significant pulmonary toxicity develops; discontinuation is required. For moderate to severe APT (significant hypoxemia, bilateral infiltrates, reduced DLCO as in this patient), corticosteroids are typically added to suppress the inflammatory component of the lung injury, with typical initial doses of prednisone 40 to 60 mg daily tapered over several months. The pharmacokinetic consideration that most complicates management is amiodarone's extremely long elimination half-life. Due to its highly lipophilic nature and high volume of distribution (estimated at 60 liters per kilogram), amiodarone accumulates extensively in adipose tissue, liver, lung, thyroid, and other organs. After discontinuation, the drug is released slowly from these tissue depots, and plasma concentrations decline with an elimination half-life measured in weeks to months (commonly cited as 40 to 55 days, but ranging from 26 to 107 days in individual patients). This means that even after the drug is stopped, amiodarone and its active metabolite desethylamiodarone continue to exert pharmacodynamic effects (including ongoing pulmonary toxicity and antiarrhythmic activity) for weeks to months. Pulmonary recovery is correspondingly slow, and improvement may not be apparent for several weeks to months after discontinuation.
Option A: Option A is incorrect: dose reduction is not an acceptable management strategy for significant APT; once clinical toxicity is established, discontinuation is required; dose reduction does not reliably halt the inflammatory process and delays definitive management.
Option B: Option B is incorrect: amiodarone is not renally eliminated; its clearance is hepatic and biliary; the long half-life is due to tissue accumulation and lipid compartment kinetics, not renal clearance; age-related CrCl decline does not affect amiodarone elimination.
Option C: Option C is incorrect: dronedarone is contraindicated in structural heart disease with reduced ejection fraction (ANDROMEDA trial) and is not appropriate for ventricular tachycardia in a patient with underlying cardiomyopathy; it is not a safe substitute in this clinical context.
Option D: Option D is incorrect: the claim that APT resolves within two to three weeks is inconsistent with amiodarone's pharmacokinetics; given the weeks-to-months half-life and tissue accumulation, pulmonary recovery takes substantially longer; corticosteroids are indicated in moderate to severe APT and are not contraindicated by macrophage-mediated clearance concerns.
3. A 78-year-old woman with hypertension and no prior cardiac history is admitted after starting levofloxacin for a respiratory tract infection. On hospital day two she develops recurrent episodes of syncope. Telemetry shows a polymorphic ventricular tachycardia with a characteristic twisting-about-the-baseline morphology, preceded each time by a pause followed by a compensatory pause. Her QTc is 580 ms. Her baseline ECG from six months ago showed a QTc of 430 ms. Her serum potassium is 3.1 mEq/L and magnesium is 0.7 mEq/L. Which of the following represents the most complete correct initial management?
A) Administer intravenous magnesium sulfate 2 g over 5 minutes as the primary pharmacological intervention, simultaneously discontinue levofloxacin, and replete potassium and magnesium to the high-normal range (potassium above 4.5 mEq/L, magnesium above 2.0 mEq/L); if episodes recur despite magnesium, initiate temporary transvenous pacing or isoproterenol infusion to increase the heart rate and shorten the QT interval, as this arrhythmia is characteristically bradycardia-dependent and pause-dependent
B) Administer intravenous amiodarone 150 mg over 10 minutes as first-line treatment for recurrent ventricular tachycardia, then initiate a maintenance infusion; amiodarone is the preferred agent for torsades de pointes because its multi-class mechanism terminates both the acute episode and addresses the underlying QT prolongation
C) Perform immediate electrical cardioversion with 200 joules synchronized; pharmacological treatment is contraindicated in pause-dependent torsades de pointes because all antiarrhythmic agents that terminate ventricular tachycardia also prolong the QT interval and risk triggering further episodes
D) Administer intravenous lidocaine as the specific antidote for fluoroquinolone-induced QT prolongation; lidocaine's Class Ib mechanism shortens action potential duration and directly counteracts the IKr blockade produced by levofloxacin, providing targeted pharmacological reversal of the triggering mechanism
E) Administer intravenous potassium chloride to correct the hypokalemia and hold further levofloxacin doses; potassium repletion alone is sufficient to normalize the QTc and prevent further torsades de pointes episodes in this patient, as the arrhythmia is driven entirely by electrolyte depletion rather than drug effect
ANSWER: A
Rationale:
This patient has classic drug-induced torsades de pointes (TdP) with multiple concurrent contributing factors: levofloxacin (a fluoroquinolone with IKr blocking properties), hypokalemia (serum potassium 3.1 mEq/L), hypomagnesemia (serum magnesium 0.7 mEq/L), and a bradycardia-pause-dependent pattern on telemetry. The correct management addresses all of these simultaneously. Intravenous magnesium sulfate (1 to 2 g IV over 5 to 10 minutes) is the first-line pharmacological treatment for TdP regardless of serum magnesium level; it suppresses EADs by inhibiting L-type calcium channel activation and reduces the amplitude of the triggered activity that initiates each TdP episode. Simultaneously, the offending QT-prolonging drug must be removed; levofloxacin must be discontinued and an alternative non-QT-prolonging antibiotic selected. Electrolyte repletion is a critical adjunct: potassium should be aggressively repleted to above 4.5 mEq/L (since hypokalemia reduces IKr current and extends APD) and magnesium to above 2.0 mEq/L. For recurrent or refractory episodes, increasing the heart rate eliminates the pause-dependent trigger. Temporary transvenous pacing to overdrive the rhythm at 90 to 100 beats per minute shortens the QT interval and prevents pauses. Isoproterenol infusion achieves the same result pharmacologically by increasing heart rate through beta-1 adrenergic receptor stimulation. This patient's bradycardia-pause-dependent pattern on telemetry specifically implicates the pause as the trigger and makes rate augmentation a particularly appropriate strategy.
Option B: Option B is incorrect: amiodarone is contraindicated in TdP because it prolongs the QT interval through Class III IKr blockade, worsening the underlying substrate; it would risk precipitating further and potentially more sustained episodes of TdP.
Option C: Option C is incorrect: immediate electrical cardioversion is appropriate for hemodynamically unstable TdP, but this patient has recurrent brief self-terminating episodes rather than sustained hemodynamically unstable VT; pharmacological management with magnesium is the correct first-line approach for this presentation, and the claim that all antiarrhythmic agents are contraindicated is incorrect.
Option D: Option D is incorrect: while lidocaine does shorten APD and may have some theoretical benefit in TdP, it is not the specific antidote for fluoroquinolone-induced QT prolongation and is not first-line treatment; magnesium is the evidence-based first-line pharmacological intervention.
Option E: Option E is incorrect: while potassium repletion is essential, it is not sufficient as sole management; the IKr blocking effect of levofloxacin is a direct pharmacological cause of QT prolongation that persists independently of the electrolyte abnormalities; both the drug and the electrolyte deficiencies must be addressed concurrently.
4. A 34-year-old man with Wolff-Parkinson-White (WPW) syndrome and an ischemic cardiomyopathy (LVEF 35%) following a myocardial infarction at age 28 presents with recurrent symptomatic episodes of pre-excited atrial fibrillation. His electrophysiologist is discussing the optimal long-term management strategy. Pharmacological options have been considered and largely excluded. Which of the following best explains why catheter ablation of the accessory pathway is the preferred definitive management in this specific patient and why pharmacological alternatives are particularly limited?
A) Catheter ablation is preferred because pharmacological rate control with AV nodal blocking agents is more effective than rhythm control for pre-excited AF, and ablation allows the safe addition of AV nodal blocking agents after the accessory pathway is eliminated
B) Catheter ablation is preferred because all antiarrhythmic agents are contraindicated in patients under 40 years of age with structural heart disease due to the heightened proarrhythmic risk in younger myocardium, leaving ablation as the only option in this demographic
C) Catheter ablation is preferred primarily because amiodarone has been shown to paradoxically increase accessory pathway conduction velocity through a beta-adrenergic agonist effect, which increases the ventricular rate during pre-excited AF and raises the risk of ventricular fibrillation in WPW patients on long-term therapy
D) Catheter ablation is the preferred definitive strategy because it eliminates the accessory pathway and its associated arrhythmia risk entirely; pharmacological options are particularly limited in this patient because structural heart disease (HFrEF from prior MI) contraindicates Class Ic agents and dronedarone, sotalol carries QT and renal concerns, and while amiodarone is the only broadly safe agent in structural heart disease, its extensive long-term organ toxicity profile is especially problematic in a 34-year-old facing decades of potential exposure
E) Catheter ablation is preferred because no pharmacological agent is capable of slowing conduction over an accessory pathway in the presence of HFrEF, making ablation the only option that can reduce the ventricular rate during pre-excited AF regardless of patient age or other clinical factors
ANSWER: D
Rationale:
This question requires integrating WPW management principles with the pharmacological constraints imposed by structural heart disease in a young patient. Catheter ablation of the accessory pathway via radiofrequency energy is guideline-supported as definitive therapy for WPW, achieving success rates above 95 percent with low complication rates, and is particularly appropriate in this patient for two converging reasons. First, it eliminates the accessory pathway permanently, removing both the risk of pre-excited AF and the associated risk of ventricular fibrillation if the pathway has a short refractory period. Second, the pharmacological alternatives are uniquely constrained in this specific patient. Class Ic agents (flecainide, propafenone) are contraindicated by the prior MI and HFrEF (CAST principle, structural heart disease contraindication). Dronedarone is contraindicated by HFrEF (ANDROMEDA trial). Sotalol carries concerns in the setting of structural heart disease and requires careful QT and renal monitoring. Procainamide or ibutilide can be used acutely for pre-excited AF termination but are not oral long-term options in this patient's profile. Amiodarone is the only agent with a reasonable safety profile in structural heart disease and is effective against accessory pathway conduction, but prescribing amiodarone to a 34-year-old facing potentially 40 or more years of therapy carries a very high cumulative probability of clinically significant organ toxicity (pulmonary fibrosis, thyroid dysfunction, hepatotoxicity, peripheral neuropathy, corneal deposits). This risk-benefit calculation strongly favors a curative ablative approach over lifelong pharmacological suppression.
Option A: Option A is incorrect: AV nodal blocking agents are contraindicated in pre-excited AF regardless of whether an accessory pathway is present or has been ablated in the past; after successful ablation, however, the accessory pathway is no longer conducting and the concern about AV nodal blockade redirecting all conduction through the accessory pathway is eliminated; but rate control is not the preferred strategy for pre-excited AF; rhythm control and pathway elimination are.
Option B: Option B is incorrect: there is no age-based absolute contraindication to antiarrhythmic drugs in patients with structural heart disease; the contraindications are mechanism-based (Class Ic in structural heart disease, dronedarone in HFrEF), not age-based.
Option C: Option C is incorrect: amiodarone does not paradoxically increase accessory pathway conduction velocity through a beta-adrenergic agonist effect; amiodarone has beta-blocking properties and actually slows accessory pathway conduction; this option contains a pharmacologically fabricated mechanism.
Option E: Option E is incorrect: pharmacological agents including procainamide and ibutilide do slow accessory pathway conduction and can be used acutely for pre-excited AF; the preferred definitive strategy is ablation for the reasons stated, not because no drug can affect accessory pathway conduction.
5. A 65-year-old woman with persistent atrial fibrillation and no structural heart disease is being evaluated for dofetilide initiation. Her baseline assessment reveals: QTc 478 ms, CrCl 44 mL/min, serum potassium 4.0 mEq/L, serum magnesium 1.8 mg/dL, and a prior hospitalization for torsades de pointes eight years ago during treatment with sotalol for a different atrial arrhythmia. Which of the following best characterizes the safety assessment for dofetilide initiation in this patient?
A) Dofetilide initiation is appropriate; the prior sotalol-associated TdP occurred with a different drug class and is not predictive of dofetilide toxicity; the QTc of 478 ms is within the acceptable initiation range and the CrCl of 44 mL/min permits initiation at a reduced dose
B) Dofetilide is contraindicated in this patient due to a combination of factors: her baseline QTc of 478 ms approaches but does not exclude initiation, but her prior TdP with sotalol represents a history of drug-induced QT-related arrhythmia that significantly elevates her individual risk; her CrCl of 44 mL/min requires tier-1 dose reduction to 250 mcg twice daily; the combination of borderline QTc, prior TdP history, and renal impairment requiring dose reduction creates an unacceptable cumulative risk profile that makes dofetilide inappropriate in this patient
C) Dofetilide initiation is appropriate at full dose (500 mcg twice daily) because her CrCl of 44 mL/min is above the 40 mL/min contraindication threshold; the baseline QTc of 478 ms and prior TdP history are not listed as contraindications in the prescribing label and do not require dose adjustment
D) Dofetilide is absolutely contraindicated because her CrCl of 44 mL/min falls below the 60 mL/min threshold below which dofetilide cannot be used safely at any dose
E) Dofetilide initiation should be deferred until the serum magnesium is corrected to above 2.0 mg/dL and the QTc is pharmacologically shortened to below 450 ms using intravenous magnesium before the first oral dose; if both targets are achieved, dofetilide can be started at the standard dose without in-hospital monitoring
ANSWER: B
Rationale:
This question requires integrating multiple simultaneous safety considerations for dofetilide initiation. Working through each factor: the CrCl of 44 mL/min is above 40 mL/min (the absolute contraindication threshold) but falls in the tier requiring dose reduction to 250 mcg twice daily per the prescribing label (the label for the AF indication specifies 500 mcg twice daily for CrCl above 60 mL/min and 250 mcg twice daily for CrCl 40 to 60 mL/min; below 40 mL/min the drug is contraindicated for this indication). The baseline QTc of 478 ms is elevated and clinically concerning: while the dofetilide label specifies contraindication when QTc exceeds 440 ms at baseline (500 ms in patients with ventricular conduction abnormalities), some sources cite 440 ms and others are more conservative. A QTc of 478 ms at baseline exceeds the 440 ms threshold and should be considered a contraindication to dofetilide initiation. Additionally, a prior history of drug-induced TdP is a well-recognized independent risk factor for future TdP with QT-prolonging drugs, reflecting an underlying predisposition to acquired long QT and enhanced sensitivity to IKr blockade. The combination of three simultaneous risk factors: baseline QTc above 440 ms, prior TdP history, and renal impairment requiring dose reduction, creates a cumulative risk profile that makes dofetilide inappropriate.
Option A: Option A is incorrect: the claim that prior sotalol-associated TdP is not predictive of dofetilide toxicity is incorrect; TdP history with any QT-prolonging drug indicates an individual predisposition that elevates risk with all agents in this class; additionally, a baseline QTc of 478 ms exceeds the 440 ms threshold and is itself a contraindication to dofetilide.
Option C: Option C is incorrect: initiating at full dose 500 mcg twice daily is incorrect for a patient with CrCl 44 mL/min, which requires dose reduction to 250 mcg twice daily per the label's tiered dosing protocol; additionally, ignoring the baseline QTc and TdP history in the safety assessment is clinically inappropriate.
Option D: Option D is incorrect: the absolute contraindication threshold for dofetilide is CrCl below 40 mL/min (for the AF indication), not below 60 mL/min; 60 mL/min is the threshold below which dose reduction is required, not the threshold for contraindication; this option misstates the label.
Option E: Option E is incorrect: dofetilide mandates in-hospital initiation with continuous QTc monitoring for a minimum of three days regardless of pre-treatment optimization; there is no protocol that permits outpatient initiation after pre-treatment magnesium correction; additionally, IV magnesium does not reliably shorten the QTc below 440 ms in patients with underlying prolongation.
6. A 59-year-old woman has been taking amiodarone 200 mg daily for six years for paroxysmal atrial fibrillation. At her annual follow-up she is asymptomatic. Her ophthalmologist notes bilateral corneal microdeposits on slit-lamp examination but confirms her visual acuity and visual fields are entirely normal. A subsequent review of systems reveals no visual symptoms. Which of the following represents the correct clinical response to this finding and correctly distinguishes it from the more serious amiodarone-related ocular complication that requires drug discontinuation?
A) Corneal microdeposits represent early amiodarone optic neuropathy and require immediate drug discontinuation; visual symptoms are typically absent in the early phase because optic neuropathy initially affects the peripheral visual field before central vision, and the patient may be entirely unaware of early field loss without formal perimetry
B) Corneal microdeposits indicate toxic amiodarone tissue concentrations in the ocular compartment; the dose should be reduced to 100 mg daily to reverse the deposits while maintaining antiarrhythmic effect, and ophthalmologic follow-up can be discontinued once slit-lamp examination confirms deposit resolution
C) Corneal microdeposits are an expected and nearly universal finding in patients on long-term amiodarone, occurring in nearly all patients after sustained exposure, and are clinically benign; they do not require amiodarone discontinuation or dose reduction; the serious amiodarone-related ocular complication requiring drug discontinuation is amiodarone optic neuropathy (AON), which involves the optic nerve rather than the cornea and presents with progressive visual loss or visual field defects
D) Corneal microdeposits are a reliable early marker that predicts subsequent development of amiodarone pulmonary toxicity and hepatotoxicity in the same patient; their presence requires urgent chest CT and liver function testing, and amiodarone should be suspended pending toxicity workup
E) Corneal microdeposits require amiodarone discontinuation only if they are bilateral and symptomatic; unilateral asymptomatic deposits represent inflammatory deposition unrelated to amiodarone, while symptomatic bilateral deposits confirm drug toxicity and mandate discontinuation to prevent progression to corneal opacification
ANSWER: C
Rationale:
Amiodarone has two clinically distinct ocular effects that must not be confused. Corneal microdeposits (vortex keratopathy) are an almost universal finding in patients on long-term amiodarone therapy, developing in more than 90 percent of patients after sustained exposure. They represent phospholipid accumulation in corneal basal epithelial cells, visible on slit-lamp examination as whorl-like deposits. Despite their striking appearance on examination, corneal microdeposits are clinically benign: they do not cause meaningful visual impairment, do not progress to corneal opacification in the vast majority of patients, and do not require amiodarone discontinuation or dose adjustment. Patients may occasionally report mild halos or photophobia, but these are generally mild and do not necessitate drug withdrawal. The serious amiodarone-related ocular complication is amiodarone optic neuropathy (AON), which involves the optic nerve and is a distinct pathological process from the corneal deposits. AON presents with progressive, often bilateral visual loss, reduced visual acuity, and visual field defects, and can result in permanent blindness if not recognized and treated promptly. When AON is suspected, amiodarone should be discontinued, though the evidence for reversal after discontinuation is mixed and some patients continue to progress. This case describes asymptomatic corneal microdeposits with normal visual acuity and fields, a benign finding that warrants documentation and ongoing ophthalmologic surveillance but not drug discontinuation.
Option A: Option A is incorrect: corneal microdeposits and amiodarone optic neuropathy are separate entities; microdeposits are not early optic neuropathy; the two complications involve different ocular structures (corneal epithelium vs. optic nerve) and have different clinical implications.
Option B: Option B is incorrect: dose reduction does not reliably reverse corneal deposits, and deposits do not indicate a threshold of ocular toxicity requiring reduction; the deposits are a pharmacological effect of amiodarone's lipid accumulation in tissue, not a marker of individual dose toxicity.
Option D: Option D is incorrect: corneal microdeposits do not predict pulmonary or hepatic toxicity; each organ toxicity of amiodarone is independently monitored through its own surveillance protocol and there is no demonstrated cross-predictive value between corneal deposits and systemic organ toxicity.
Option E: Option E is incorrect: corneal microdeposits are characteristically bilateral in amiodarone-treated patients because the drug is systemically distributed; unilateral deposits would warrant evaluation for a different etiology; the concept that symptomatic bilateral deposits mandate discontinuation does not reflect the clinical standard, which is to discontinue for AON (optic nerve disease), not for corneal deposits.
7. A 71-year-old man with sick sinus syndrome has a permanent pacemaker programmed to a lower rate limit of 60 beats per minute. He has no structural heart disease and develops symptomatic paroxysmal atrial fibrillation. His cardiologist considers flecainide for rhythm control. A colleague raises concerns that flecainide is contraindicated in sick sinus syndrome. Which of the following best explains the correct reasoning and why pacemaker support alters the risk-benefit calculation?
A) The concern is valid and the pacemaker does not change it; flecainide is contraindicated in sick sinus syndrome because its use-dependent sodium channel block in the His-Purkinje system produces irreversible bundle branch block that the pacemaker cannot correct, creating permanent ventricular conduction abnormalities regardless of backup pacing
B) The concern is valid and unchanged; the pacemaker provides a backup ventricular rate but does not prevent the primary mechanism of flecainide proarrhythmia in sick sinus syndrome, which is acceleration of the atrial flutter rate to 400 beats per minute through loss of use-dependent block at slow atrial rates
C) The concern is partially valid; flecainide can be used with sick sinus syndrome if the serum potassium is maintained above 4.5 mEq/L, because hypokalemia is the specific trigger for sinus node suppression by Class Ic agents; the pacemaker provides no additional safety margin beyond electrolyte optimization
D) The concern is partially valid but overstated; flecainide can suppress sinus node function and worsen existing sinus node disease, potentially causing symptomatic bradycardia or sinus arrest; however, in a patient with a permanent pacemaker providing a reliable lower rate limit of 60 beats per minute, the bradycardia risk is mitigated by guaranteed backup pacing, making flecainide a reasonable choice in this pacemaker-dependent patient without structural heart disease
E) The concern is not valid; flecainide has no effect on sinus node automaticity because it selectively blocks fast sodium channels, which are absent in the sinoatrial node; the sinus node depolarizes via calcium channels and is therefore completely unaffected by any Class I antiarrhythmic agent regardless of pacemaker status
ANSWER: D
Rationale:
Flecainide and other Class Ic agents can suppress sinus node automaticity and worsen existing sinus node dysfunction. In patients with sick sinus syndrome who do not have a pacemaker, this effect can cause clinically significant bradycardia, sinus pauses, or sinus arrest, making flecainide relatively contraindicated without pacemaker backup. The colleague's concern is therefore valid in principle. However, the presence of a permanent pacemaker with a programmed lower rate limit of 60 beats per minute fundamentally changes the risk calculus. If flecainide suppresses the patient's dysfunctional sinus node, the pacemaker detects the resulting bradycardia or pause and fires reliably to maintain the minimum rate, preventing symptomatic bradycardia or arrest. This pacemaker-mediated safety net allows Class Ic therapy to be used in sick sinus syndrome patients who would otherwise be at risk from the drug's sinus node suppression. Since this patient has no structural heart disease (confirming the absence of the CAST-based contraindication), flecainide is a pharmacologically appropriate choice for AF rhythm control once the sinus node suppression concern is addressed by pacemaker backup. Co-administration of an AV nodal blocking agent (beta-blocker or rate-limiting calcium channel blocker) remains recommended to prevent 1:1 flutter conduction if flecainide converts AF to flutter.
Option A: Option A is incorrect: flecainide does not produce irreversible bundle branch block; its conduction-slowing effects are pharmacodynamic and rate-dependent, reversing as drug plasma concentrations decline; the pacemaker does address ventricular rate support if needed.
Option B: Option B is incorrect: flecainide slows the atrial flutter rate rather than accelerating it; at slow rates, use-dependent block diminishes (reverse of what this option states); the flutter rate concern is 1:1 AV conduction at a slowed flutter rate, not acceleration above 400 beats per minute.
Option C: Option C is incorrect: hypokalemia does not specifically trigger sinus node suppression by Class Ic agents; flecainide's sinus node effect is a direct pharmacological consequence of sodium channel blockade in nodal tissue, not an electrolyte-mediated effect.
Option E: Option E is incorrect: while it is true that SA node pacemaker cells depolarize primarily via calcium channels rather than fast sodium channels, flecainide does have measurable effects on sinus node function in patients with pre-existing sinus node disease, likely through effects on peripheral Purkinje-like cells around the node and through indirect mechanisms; the claim that Class I agents have no effect on the sinus node is an overstatement.
8. A 58-year-old man with ischemic cardiomyopathy (LVEF 30%) is resuscitated from out-of-hospital ventricular fibrillation. Coronary angiography shows no new culprit lesion and his prior revascularization is intact; the arrest is attributed to a primary arrhythmic event from scar-related re-entry. He is hemodynamically stable after 48 hours. His electrophysiologist discusses secondary prevention. Which of the following best describes the evidence-based approach to secondary prevention and the appropriate role of antiarrhythmic drug therapy in this patient?
A) Implantable cardioverter-defibrillator (ICD) implantation is the primary evidence-based intervention for secondary prevention of sudden cardiac death in this patient; amiodarone may be added as an adjunct to reduce ICD shock burden (particularly appropriate if the patient has frequent ICD therapies), but amiodarone monotherapy without ICD implantation is not an appropriate primary prevention strategy in a patient who has already survived cardiac arrest from ventricular fibrillation
B) Amiodarone alone is the preferred secondary prevention strategy for VF in ischemic cardiomyopathy because it has demonstrated mortality benefit in this population in the EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Arrhythmia Trial) trials, providing superior protection compared with ICD implantation at comparable cost and without the procedural risk
C) Catheter ablation of the VF focus is the first-line intervention and should precede ICD implantation; ablation eliminates the re-entrant substrate and renders ICD implantation unnecessary in the majority of patients with scar-related VF
D) Sotalol is the preferred antiarrhythmic for secondary VF prevention in ischemic cardiomyopathy because its combined Class II and Class III properties provide both beta-blockade and QT prolongation, and it was shown superior to ICD therapy in the AVID trial (Antiarrhythmics versus Implantable Defibrillators) subgroup analysis of patients with LVEF above 25%
E) Neither ICD nor antiarrhythmic drugs are indicated in this patient because his VF occurred in the context of prior revascularization; the presumed mechanism is reperfusion arrhythmia rather than scar-based re-entry, and secondary prevention pharmacotherapy is reserved for patients with demonstrable scar on cardiac MRI
ANSWER: A
Rationale:
Secondary prevention of sudden cardiac death in a patient who has survived cardiac arrest from ventricular fibrillation attributable to structural heart disease is among the clearest evidence-based indications for ICD implantation. The AVID trial (Antiarrhythmics versus Implantable Defibrillators), CASH trial (Cardiac Arrest Study Hamburg), and CIDS trial (Canadian Implantable Defibrillator Study) all demonstrated that ICD therapy is superior to antiarrhythmic drug therapy (primarily amiodarone) for secondary prevention of sudden cardiac death in patients who survived VF or hemodynamically destabilizing VT. ICD implantation is therefore the cornerstone of secondary prevention in this patient. Amiodarone has an established adjunctive role in ICD patients: it reduces the frequency of ICD shocks (both appropriate and inappropriate), suppresses triggering ventricular ectopy, and may slow tachycardia rates to allow antitachycardia pacing (ATP) rather than shock therapy. In patients with frequent ICD therapies despite optimal medical therapy and programming, amiodarone is a guideline-recommended adjunct. However, amiodarone monotherapy without ICD implantation is not a guideline-supported secondary prevention strategy for VF survivors with structural heart disease who are eligible for ICD.
Option B: Option B is incorrect: EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Arrhythmia Trial) evaluated amiodarone in post-MI patients for primary prevention of arrhythmic death; neither demonstrated superiority over ICD for secondary prevention in VF survivors, and the evidence base established in AVID, CASH, and CIDS consistently shows ICD superiority.
Option C: Option C is incorrect: catheter ablation of VF in ischemic cardiomyopathy can reduce VF burden and ICD shocks, particularly when the VF is triggered by a specific premature ventricular contraction focus, but it does not replace ICD implantation; ablation is an adjunct in this context, not a curative first-line intervention that eliminates the need for ICD.
Option D: Option D is incorrect: sotalol was the comparator arm in the AVID trial and was inferior to ICD for secondary prevention; additionally, sotalol's use in severe HFrEF (LVEF 30%) is complicated by structural heart disease concerns and renal clearance dependence; there is no approved subgroup analysis showing sotalol superiority to ICD at any ejection fraction threshold.
Option E: Option E is incorrect: the clinical assessment explicitly attributes the arrest to scar-related re-entry rather than reperfusion arrhythmia (no new culprit lesion, stable revascularization, prior scar substrate); secondary prevention ICD implantation is indicated; cardiac MRI scar demonstration is not required to establish eligibility.
9. A 52-year-old woman with obstructive hypertrophic cardiomyopathy (LVEF 75%, dynamic left ventricular outflow tract gradient of 55 mmHg at rest) develops persistent atrial fibrillation that is causing significant symptomatic deterioration due to loss of the atrial contribution to ventricular filling. Her cardiologist considers pharmacological options for both rate control and rhythm control. Which of the following best describes the optimal antiarrhythmic approach in this specific clinical context?
A) Verapamil is the preferred rate control agent because its combined negative inotropic and chronotropic properties reduce the outflow tract gradient while simultaneously slowing the ventricular rate in AF, making it uniquely positioned to address both the rate and the obstructive physiology simultaneously
B) Flecainide is the appropriate rhythm control agent because hypertrophic cardiomyopathy without a prior MI or coronary artery disease does not meet the structural heart disease definition of the CAST contraindication; Class Ic agents are therefore safe in this population for AF rhythm control
C) Amiodarone is the only antiarrhythmic appropriate in hypertrophic cardiomyopathy because its multi-class profile avoids the pharmacological mechanisms that worsen outflow tract obstruction, and it is the recommended first-line agent for all AF rhythm control in this disease according to guideline consensus
D) Sotalol is preferred because its dual Class II and Class III properties provide simultaneous rate control and rhythm control without affecting ventricular contractility, and it has been specifically validated in randomized trials for AF rhythm control in hypertrophic cardiomyopathy without negative inotropic concerns
E) Disopyramide combined with a beta-blocker or rate-limiting calcium channel blocker is an appropriate pharmacological strategy in this patient: disopyramide's pronounced negative inotropic effect specifically reduces the dynamic left ventricular outflow tract gradient (a guideline-recognized niche indication), while the co-administered AV nodal blocking agent provides rate control in AF and counteracts disopyramide's antimuscarinic acceleration of AV nodal conduction
ANSWER: E
Rationale:
Hypertrophic obstructive cardiomyopathy (HOCM) with AF requires a pharmacological strategy that simultaneously addresses rate control, potential rhythm control, and the unique hemodynamic consequences of the obstructive physiology. Disopyramide occupies a specific niche in this context. Its pronounced negative inotropic effect reduces myocardial contractility and decreases the dynamic left ventricular outflow tract (LVOT) gradient, which is the gradient driven by hypercontractile systolic function and the Venturi effect of the hypertrophied septum on the anterior mitral leaflet. Current hypertrophic cardiomyopathy guidelines recognize disopyramide as a reasonable pharmacological option for reducing the LVOT gradient in symptomatic patients, specifically because of this negative inotropic property that is otherwise an adverse effect in most clinical contexts. However, disopyramide also has clinically significant antimuscarinic (anticholinergic) properties that block vagal tone at the AV node, potentially enhancing AV nodal conduction and allowing faster ventricular rates during AF, the opposite of what is desired. For this reason, disopyramide for HOCM must always be combined with an AV nodal blocking agent (beta-blocker or rate-limiting calcium channel blocker such as verapamil or diltiazem) to prevent AV nodal acceleration. The combination addresses both the hemodynamic goal (gradient reduction via disopyramide) and the rate control goal (AV nodal slowing via the co-agent).
Option A: Option A is incorrect: while verapamil does reduce the LVOT gradient through negative inotropy and is used in HOCM, there is an important caveat: verapamil's vasodilatory properties can reduce afterload and may transiently worsen the outflow gradient in some HOCM patients, particularly during loading; it is not universally the first-line agent and must be used carefully in the obstructive physiology context; beta-blockers are more commonly first-line for HOCM rate control.
Option B: Option B is incorrect: hypertrophic cardiomyopathy does constitute structural heart disease for pharmacological risk stratification purposes, even without coronary artery disease; Class Ic agents are not routinely recommended in HOCM and are generally avoided given the structural substrate; the CAST contraindication is specifically about post-MI structural disease, but the pharmacological principle of avoiding Class Ic agents in structural heart disease extends to other cardiomyopathies in clinical practice guidelines for HOCM.
Option C: Option C is incorrect: while amiodarone is a guideline-mentioned option for AF in HOCM, it is not described as the only appropriate antiarrhythmic; disopyramide and other agents have established roles; describing amiodarone as universally first-line for all HOCM AF is an overstatement.
Option D: Option D is incorrect: sotalol has not been specifically validated in randomized trials for AF in HOCM; its structural heart disease profile (particularly in patients with outflow obstruction and hypertrophy) requires care; while sotalol is sometimes used in HOCM patients, it is not the preferred agent with the specific gradient-reducing benefit that disopyramide provides.
10. A 29-year-old woman at 26 weeks of gestation presents to the emergency department with a narrow-complex regular tachycardia at 196 beats per minute. She is hemodynamically stable, anxious, and reporting palpitations for the past two hours. Vagal maneuvers including Valsalva and carotid sinus massage have no effect. Her obstetrician and cardiologist jointly assess the situation and discuss pharmacological treatment. Which of the following best describes the correct management approach in this specific clinical context?
A) Intravenous metoprolol is the preferred first-line pharmacological agent for SVT termination in pregnancy because it has the longest safety record in obstetric use, is well-studied for fetal heart rate effects, and is the only antiarrhythmic classified as FDA Pregnancy Category B throughout all trimesters
B) Intravenous adenosine is the pharmacological treatment of choice for acute SVT termination in this pregnant patient; adenosine has a half-life of less than 10 seconds and does not cross the placenta in clinically significant amounts due to rapid maternal metabolism by adenosine deaminase in red blood cells before reaching the fetal circulation, making it the safest and most appropriate first-line agent
C) Intravenous verapamil is preferred over adenosine in pregnancy because adenosine crosses the placenta and has been shown in multiple clinical trials to cause fetal bradycardia and fetal atrioventricular block at doses used for maternal SVT termination; verapamil avoids this fetal risk while providing equivalent efficacy
D) Electrical cardioversion with 50 to 100 joules synchronized is the preferred initial intervention in all cases of maternal SVT during pregnancy regardless of hemodynamic stability, because pharmacological agents pose unacceptable fetal risks during the second trimester and cardioversion is associated with a lower rate of fetal arrhythmia than any antiarrhythmic drug
E) All pharmacological treatment should be withheld and the patient should be monitored for spontaneous termination because SVT in pregnancy is virtually always self-terminating within four hours; intervening with adenosine or electrical cardioversion poses greater risk to the fetus than the SVT itself and violates the principle of minimal pharmacological intervention in the second trimester
ANSWER: B
Rationale:
Acute management of SVT in a hemodynamically stable pregnant patient follows the same initial sequence as in non-pregnant patients: vagal maneuvers first, then adenosine, with adenosine remaining the drug of choice for acute termination. Adenosine's unique pharmacokinetic profile makes it particularly well-suited for use in pregnancy. Its half-life is less than 10 seconds due to rapid uptake and deamination by red blood cells and vascular endothelium. Because adenosine is metabolized in the maternal circulation before reaching the uteroplacental circulation in meaningful concentrations, placental transfer is minimal. Clinical experience with adenosine in pregnancy is substantial, and case series and clinical reports consistently support its safety for both mother and fetus. The drug terminates the re-entrant SVT circuit through transient AV nodal block and sinus rhythm resumes within seconds. For ongoing or recurrent SVT during pregnancy, longer-term rate control options include beta-blockers (with attention to fetal growth restriction with atenolol) or digoxin; and for rhythm control, flecainide or sotalol have been used with monitoring. Electrical cardioversion remains safe throughout pregnancy if drug therapy fails or if the patient is hemodynamically compromised, and should not be withheld if indicated.
Option A: Option A is incorrect: intravenous metoprolol is not the first-line pharmacological agent for acute SVT termination in pregnancy; adenosine is preferred for acute termination because of its rapid and targeted mechanism; metoprolol's slower onset and systemic effects make it less appropriate for acute cardioversion of SVT.
Option C: Option C is incorrect: this option inverts the correct clinical evidence; adenosine is well-established as safe in pregnancy due to its minimal placental transfer and ultra-short half-life; verapamil is actually associated with more adverse hemodynamic effects in pregnancy (maternal hypotension, reduced uterine blood flow) and is generally not preferred over adenosine for acute SVT termination in pregnant patients.
Option D: Option D is incorrect: immediate electrical cardioversion is not required for hemodynamically stable SVT; pharmacological termination with adenosine is the appropriate first-line approach for stable patients; cardioversion is reserved for hemodynamically unstable patients or those who fail pharmacological therapy.
Option E: Option E is incorrect: SVT in pregnancy, while sometimes self-limiting, can persist for hours and poses hemodynamic risks to both mother and fetus if prolonged; withholding adenosine based on a principle of non-intervention is not appropriate clinical management when a safe, effective, and rapidly acting treatment exists.
11. A 64-year-old man with persistent atrial fibrillation and no structural heart disease is being considered for sotalol initiation. His cardiologist reviews the pre-initiation requirements. Which of the following correctly identifies all of the mandatory pre-initiation assessments and monitoring requirements that the FDA prescribing label specifies must be completed before and during sotalol initiation?
A) Baseline ECG to document QTc, baseline serum creatinine with CrCl calculation, and outpatient ECG monitoring for seven days after the first dose; in-hospital admission is not required for sotalol initiation in patients with no prior cardiac history and a QTc below 450 ms
B) Baseline QTc and CrCl only; the prescribing label does not specify electrolyte requirements because sotalol does not significantly block potassium channels at standard doses; in-hospital monitoring is required only for patients with prior TdP history or baseline QTc above 440 ms
C) Baseline QTc measurement, CrCl calculation, and serum electrolytes (potassium and magnesium) must be confirmed before initiation; in-hospital initiation with continuous telemetry monitoring is required for all patients, with QTc measurement after each dose for a minimum of three days or five to six doses at the maintenance dosing interval, whichever is longer; sotalol is contraindicated if baseline QTc exceeds 450 ms (500 ms in patients with ventricular conduction abnormalities) or if CrCl is below 40 mL/min for the AF indication
D) Baseline ECG, renal function, and cardiac stress testing to rule out inducible ischemia are required; sotalol is contraindicated in patients with any inducible ST depression because use-dependent sodium channel block in ischemic myocardium creates proarrhythmic risk; in-hospital initiation is required for the first 48 hours only
E) Baseline QTc, renal function, and electrolytes are required; in-hospital monitoring is required only for high-risk patients (prior TdP, QTc above 470 ms, or CrCl below 60 mL/min); low-risk patients with QTc below 440 ms, CrCl above 60 mL/min, and normal electrolytes may begin sotalol as outpatients with a follow-up ECG at one week
ANSWER: C
Rationale:
The FDA prescribing label for sotalol (Betapace AF) for the atrial fibrillation indication specifies a precise and non-negotiable initiation protocol. Before initiating sotalol, the following must be established: baseline QTc (contraindicated if QTc exceeds 450 ms, or 500 ms in patients with bundle branch block or intraventricular conduction delay); CrCl calculated by a validated method (contraindicated if CrCl is below 40 mL/min for the AF indication); and serum electrolytes including potassium and magnesium, which must be within normal range before initiation because hypokalemia and hypomagnesemia potentiate sotalol's QT-prolonging effect and must be corrected first. Sotalol initiation must occur in a facility capable of continuous cardiac monitoring and cardiac resuscitation, with the patient admitted for a minimum of three days or five to six doses at the maintenance dosing interval, whichever is longer, with QTc measurement after each dose. If the QTc extends beyond 500 ms during initiation monitoring, the dose must be reduced or the drug discontinued. There is no provision in the label for outpatient initiation under any circumstances, regardless of risk stratification. This mandatory in-hospital initiation protocol distinguishes sotalol from most other antiarrhythmic agents and reflects the clinically demonstrated risk of TdP during the initiation period.
Option A: Option A is incorrect: outpatient initiation of sotalol is not permitted under the FDA label for the AF indication; the prescribing label mandates in-hospital initiation for all patients regardless of prior cardiac history or baseline QTc.
Option B: Option B is incorrect: electrolyte assessment is specifically required before sotalol initiation because hypokalemia and hypomagnesemia directly potentiate the drug's QT-prolonging effect; the claim that electrolytes are not required because sotalol does not block potassium channels is pharmacologically wrong; IKr blockade is sotalol's primary Class III mechanism.
Option D: Option D is incorrect: cardiac stress testing is not specified in the sotalol prescribing label as a pre-initiation requirement; sotalol is not contraindicated based on inducible ischemia on stress testing; additionally, sotalol is a beta-blocker and Class III agent, not a sodium channel blocker, so use-dependent sodium channel block in ischemic myocardium is not the relevant mechanism.
Option E: Option E is incorrect: the sotalol label does not stratify patients into in-hospital and outpatient initiation groups; all patients require in-hospital initiation regardless of baseline risk factors; the risk stratification approach described in this option does not reflect label requirements.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.